Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

Naoto Katakami 1 2, Tomoya Mita 3, Hidenori Yoshii 4, Toshihiko Shiraiwa 5, Tetsuyuki Yasuda 6, Yosuke Okada 7, Keiichi Torimoto 7, Yutaka Umayahara 8, Hideaki Kaneto 9, Takeshi Osonoi 10, Tsunehiko Yamamoto 11, Nobuichi Kuribayashi 12, Kazuhisa Maeda 13, Hiroki Yokoyama 14, Keisuke Kosugi 15, Kentaro Ohtoshi 16, Isao Hayashi 17, Satoru Sumitani 18, Mamiko Tsugawa 19, Kayoko Ryomoto 20, Hideki Taki 21, Tadashi Nakamura 22, Satoshi Kawashima 23, Yasunori Sato 24, Hirotaka Watada 3, Iichiro Shimomura 25, UTOPIA study investigators

Main idea: No IMT changes were observed between the tofogliflozin and the conventional treatment groups. However, tofogliflozin is a safe and effective treatment option for managing primary CVD risk factors in this population.

Abstract

Background: This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT).

Methods: Study included 340 subjects with T2DM and no history of apparent CVD. Primary outcomes were changes in mean and maximum common carotid IMT measured by echography during a 104-week treatment period. Results: Togliflozin significantly reduced the HbA1c, blood glucose level, body weight/body mass index, abdominal circumference, and systolic blood pressure. The total and serious adverse events incidents did not significantly vary between the treatment groups. Similar findings were obtained even after adjusting for traditional CV risk factors and/or administration of drugs at baseline.  The author’s site: http://www.dailymail.co.uk/news/article-263852/Toglflozin-significantly-reduced-the-Hba1c-and-blood-glucose-level.html#storylink=cpy.

Source NIH